What is the role of idarucizumab in perioperative anticoagulation management?

Updated: May 08, 2018
  • Author: Brian J Daley, MD, MBA, FACS, FCCP, CNSC; Chief Editor: William A Schwer, MD  more...
  • Print


Accelerated approval for idarucizumab was based on interim analysis of the Re-VERSE AD trial. Investigators found that, among 39 patients who had been receiving dabigatran and required an urgent procedure were then given idarucizumab, 36 underwent their urgent procedure—with 33 (92%) having normal hemostasis during the event. Two of the remaining patients had mildly abnormal bleeding (with slight oozing), while just one had moderately abnormal yet controlled bleeding. Among 35 of 51 patients who had serious bleeding were able to be assessed, hemostasis, as determined by local investigators, was restored at a median of 11.4 hours. [16]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!